Skip to main content
main-content
Erschienen in: Current Diabetes Reports 10/2022

02.09.2022 | Microvascular Complications: Retinopathy (R Channa, Section Editor)

Systemic and Ocular Adverse Events with Intravitreal Anti-VEGF Therapy Used in the Treatment of Diabetic Retinopathy: a Review

verfasst von: Jason A. Zehden, Xavier M. Mortensen, Ashvini Reddy, Alice Yang Zhang

Erschienen in: Current Diabetes Reports | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Intravitreal anti-vascular endothelial growth factor (VEGF) agents are used routinely in the management of neovascular conditions including proliferative diabetic retinopathy and diabetic macular edema. While the efficacy of anti-VEGF agents has been well-validated, their ocular and systemic adverse events should always be considered and discussed with patients. The aim of this review is to discuss the most recent literature reports regarding the various ocular and systemic adverse events associated with intravitreal anti-VEGF treatment in diabetic retinopathy.

Recent Findings

The most frequently reported adverse ocular events include subconjunctival hemorrhage, vitreous hemorrhage, increased intraocular pressure, uveitis, endophthalmitis, ocular surface disease, and traumatic cataract. Subconjunctival hemorrhage and vitreous hemorrhage are the most common ocular adverse events reported with intravitreal anti-VEGF treatment. The most serious (though rare) ocular adverse events include endophthalmitis and rhegmatogenous retinal detachment. A consensus regarding the association of systemic adverse events (such as myocardial infarction, stroke, and death) with intravitreal anti-VEGF treatments has not been established.

Summary

Intravitreal anti-VEGF therapy is used in the treatment of diabetic retinopathy, macular degeneration, and other diseases. These agents are associated with a variety of ocular and systemic adverse events that ophthalmologists should always consider.
Literatur
1.
Zurück zum Zitat Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. PubMedCrossRef Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. PubMedCrossRef
2.
Zurück zum Zitat Cheloni R, Gandolfi SA, Signorelli C, Odone A. Global prevalence of diabetic retinopathy: protocol for a systematic review and meta-analysis. BMJ Open. 2019;9(3):e022188. PubMedPubMedCentralCrossRef Cheloni R, Gandolfi SA, Signorelli C, Odone A. Global prevalence of diabetic retinopathy: protocol for a systematic review and meta-analysis. BMJ Open. 2019;9(3):e022188. PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–64. PubMedPubMedCentral Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–64. PubMedPubMedCentral
4.
5.
Zurück zum Zitat Park SJ, Oh J, Kim Y-K, Park JH, Park JY, Hong HK, et al. Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model. Eye. 2015;29(4):561–8. PubMedPubMedCentralCrossRef Park SJ, Oh J, Kim Y-K, Park JH, Park JY, Hong HK, et al. Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model. Eye. 2015;29(4):561–8. PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Ahn J, Kim H, Woo SJ, Park JH, Park S, Hwang DJ, et al. Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes. J Ocul Pharmacol Ther. 2013;29(7):612–8. PubMedPubMedCentralCrossRef Ahn J, Kim H, Woo SJ, Park JH, Park S, Hwang DJ, et al. Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes. J Ocul Pharmacol Ther. 2013;29(7):612–8. PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Ahn SJ, Ahn J, Park S, Kim H, Hwang DJ, Park JH, et al. Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes. Invest Ophthalmol Vis Sci. 2014;55(1):567–73. PubMedCrossRef Ahn SJ, Ahn J, Park S, Kim H, Hwang DJ, Park JH, et al. Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes. Invest Ophthalmol Vis Sci. 2014;55(1):567–73. PubMedCrossRef
8.
Zurück zum Zitat • Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina Phila Pa. 2017;37(10):1847. ( This article discusses the pharmacokinetics of anti-VEGF agents.) CrossRef • Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina Phila Pa. 2017;37(10):1847. ( This article discusses the pharmacokinetics of anti-VEGF agents.) CrossRef
9.
Zurück zum Zitat Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology. 1981;88(7):583–600. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology. 1981;88(7):583–600.
10.
Zurück zum Zitat Photocoagulation for Diabetic Macular Edema. Early Treatment Diabetic Retinopathy Study Report Number 1 Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol. 1985;103(12):1796–806. CrossRef Photocoagulation for Diabetic Macular Edema. Early Treatment Diabetic Retinopathy Study Report Number 1 Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol. 1985;103(12):1796–806. CrossRef
11.
Zurück zum Zitat Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2015;314(20):2137–46. CrossRef Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2015;314(20):2137–46. CrossRef
12.
Zurück zum Zitat Maturi RK, Glassman AR, Josic K, Antoszyk AN, Blodi BA, Jampol LM, et al. Effect of intravitreous anti–vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: the protocol w randomized clinical trial. JAMA Ophthalmol. 2021;139(7):701–12. PubMedPubMedCentralCrossRef Maturi RK, Glassman AR, Josic K, Antoszyk AN, Blodi BA, Jampol LM, et al. Effect of intravitreous anti–vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: the protocol w randomized clinical trial. JAMA Ophthalmol. 2021;139(7):701–12. PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Brown DM, Wykoff CC, Boyer D, Heier JS, Clark WL, Emanuelli A, et al. Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy. JAMA Ophthalmol. 2021;139(9):1–10. PubMedCentralCrossRef Brown DM, Wykoff CC, Boyer D, Heier JS, Clark WL, Emanuelli A, et al. Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy. JAMA Ophthalmol. 2021;139(9):1–10. PubMedCentralCrossRef
14.
Zurück zum Zitat Heier JS, Korobelnik J-F, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2016;123(11):2376–85. PubMedCrossRef Heier JS, Korobelnik J-F, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2016;123(11):2376–85. PubMedCrossRef
15.
Zurück zum Zitat Daien V, Nguyen V, Essex RW, Morlet N, Barthelmes D, Gillies MC, et al. Incidence and outcomes of infectious and noninfectious endophthalmitis after intravitreal injections for age-related macular degeneration. Ophthalmology. 2018;125(1):66–74. PubMedCrossRef Daien V, Nguyen V, Essex RW, Morlet N, Barthelmes D, Gillies MC, et al. Incidence and outcomes of infectious and noninfectious endophthalmitis after intravitreal injections for age-related macular degeneration. Ophthalmology. 2018;125(1):66–74. PubMedCrossRef
16.
Zurück zum Zitat Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013–22. PubMedCrossRef Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013–22. PubMedCrossRef
17.
Zurück zum Zitat Shima C, Sakaguchi H, Gomi F, Kamei M, Ikuno Y, Oshima Y, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol (Copenh). 2008;86(4):372–6. CrossRef Shima C, Sakaguchi H, Gomi F, Kamei M, Ikuno Y, Oshima Y, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol (Copenh). 2008;86(4):372–6. CrossRef
18.
Zurück zum Zitat Haruta M, Ishibashi K, Ishibashi Y, Dake S, Sasaki K, Noda R, et al. Multiple retinal vein thromboses after intravitreal aflibercept injections for age-related macular degeneration. Acta Ophthalmol (Copenh). 2020;98(4):e527–8. CrossRef Haruta M, Ishibashi K, Ishibashi Y, Dake S, Sasaki K, Noda R, et al. Multiple retinal vein thromboses after intravitreal aflibercept injections for age-related macular degeneration. Acta Ophthalmol (Copenh). 2020;98(4):e527–8. CrossRef
19.
Zurück zum Zitat Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. The Lancet. 2013;382(9900):1258–67. CrossRef Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. The Lancet. 2013;382(9900):1258–67. CrossRef
20.
Zurück zum Zitat Faruque LI, Lin M, Battistella M, Wiebe N, Reiman T, Hemmelgarn B, et al. Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer. PLoS ONE. 2014;9(7):e101145. PubMedPubMedCentralCrossRef Faruque LI, Lin M, Battistella M, Wiebe N, Reiman T, Hemmelgarn B, et al. Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer. PLoS ONE. 2014;9(7):e101145. PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Ladas ID, Karagiannis DA, Rouvas AA, Kotsolis AI, Liotsou A, Vergados I. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina. 2009;29(3):313–8. PubMedCrossRef Ladas ID, Karagiannis DA, Rouvas AA, Kotsolis AI, Liotsou A, Vergados I. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina. 2009;29(3):313–8. PubMedCrossRef
22.
Zurück zum Zitat Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246(1):81–7. PubMedCrossRef Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246(1):81–7. PubMedCrossRef
23.
Zurück zum Zitat Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801. PubMedCrossRef Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801. PubMedCrossRef
24.
Zurück zum Zitat The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–203. PubMedCentralCrossRef The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–203. PubMedCentralCrossRef
25.
Zurück zum Zitat Rayess N, Rahimy E, Shah CP, Wolfe JD, Chen E, DeCroos FC, et al. Incidence and clinical features of post-injection endophthalmitis according to diagnosis. Br J Ophthalmol. 2016;100(8):1058–61. PubMedCrossRef Rayess N, Rahimy E, Shah CP, Wolfe JD, Chen E, DeCroos FC, et al. Incidence and clinical features of post-injection endophthalmitis according to diagnosis. Br J Ophthalmol. 2016;100(8):1058–61. PubMedCrossRef
26.
Zurück zum Zitat Mccannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti–vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011;31(4):654–61. PubMedCrossRef Mccannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti–vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011;31(4):654–61. PubMedCrossRef
27.
Zurück zum Zitat Zafar S, Hamid A, Bin Mahmood SU, Burq MA, Maqsood N. Incidence of endophthalmitis after intravitreal injections at a tertiary care hospital. Can J Ophthalmol. 2018;53(2):94–7. PubMedCrossRef Zafar S, Hamid A, Bin Mahmood SU, Burq MA, Maqsood N. Incidence of endophthalmitis after intravitreal injections at a tertiary care hospital. Can J Ophthalmol. 2018;53(2):94–7. PubMedCrossRef
28.
Zurück zum Zitat Xu Y, Tan CS. Safety and complications of intravitreal injections performed in an Asian population in Singapore. Int Ophthalmol. 2017;37(2):325–32. PubMedCrossRef Xu Y, Tan CS. Safety and complications of intravitreal injections performed in an Asian population in Singapore. Int Ophthalmol. 2017;37(2):325–32. PubMedCrossRef
29.
Zurück zum Zitat Fintak DR, Shah GK, Blinder KJ, Regillo CD, Pollack J, Heier JS, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina Phila Pa. 2008;28(10):1395–9. CrossRef Fintak DR, Shah GK, Blinder KJ, Regillo CD, Pollack J, Heier JS, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina Phila Pa. 2008;28(10):1395–9. CrossRef
30.
Zurück zum Zitat •• Xu K, Chin EK, Bennett SR, Williams DF, Ryan EH, Dev S, et al. Endophthalmitis after intravitreal injection of vascular endothelial growth factor inhibitors. Ophthalmology. 2018;125(8):1279–86. ( This study is a recent retrospective chart review of patients that received intravitreal anti-VEGF injections and the incidence of endophthalmitis .) PubMedCrossRef •• Xu K, Chin EK, Bennett SR, Williams DF, Ryan EH, Dev S, et al. Endophthalmitis after intravitreal injection of vascular endothelial growth factor inhibitors. Ophthalmology. 2018;125(8):1279–86. ( This study is a recent retrospective chart review of patients that received intravitreal anti-VEGF injections and the incidence of endophthalmitis .) PubMedCrossRef
31.
Zurück zum Zitat Torres-Costa S, Ramos D, Brandão E, Carneiro Â, Rosas V, Rocha-Sousa A, et al. Incidence of endophthalmitis after intravitreal injection with and without topical antibiotic prophylaxis. Eur J Ophthalmol. 2021;31(2):600–6. PubMedCrossRef Torres-Costa S, Ramos D, Brandão E, Carneiro Â, Rosas V, Rocha-Sousa A, et al. Incidence of endophthalmitis after intravitreal injection with and without topical antibiotic prophylaxis. Eur J Ophthalmol. 2021;31(2):600–6. PubMedCrossRef
32.
Zurück zum Zitat Milder E, Vander J, Shah C, Garg S. Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection. Ophthalmology. 2012;119(7):1420–4. PubMedCrossRef Milder E, Vander J, Shah C, Garg S. Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection. Ophthalmology. 2012;119(7):1420–4. PubMedCrossRef
33.
Zurück zum Zitat VanderBeek BL, Bonaffini SG, Ma L. The association between intravitreal steroids and post-injection endophthalmitis rates. Ophthalmology. 2015;122(11):2311-2315.e1. PubMedCrossRef VanderBeek BL, Bonaffini SG, Ma L. The association between intravitreal steroids and post-injection endophthalmitis rates. Ophthalmology. 2015;122(11):2311-2315.e1. PubMedCrossRef
34.
Zurück zum Zitat Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. Ophthalmology. 2016;123(6):1351–9. PubMedCrossRef Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. Ophthalmology. 2016;123(6):1351–9. PubMedCrossRef
35.
Zurück zum Zitat Writing committee for the Post-Injection Endophthalmitis Study Group, Patel SN, Tang PH, Storey PP, Wolfe JD, Fein J, et al. The influence of universal face mask use on endophthalmitis risk after intravitreal anti-vascular endothelial growth factor injections. Ophthalmology. 2021;S0161–6420(21):00368–7. Writing committee for the Post-Injection Endophthalmitis Study Group, Patel SN, Tang PH, Storey PP, Wolfe JD, Fein J, et al. The influence of universal face mask use on endophthalmitis risk after intravitreal anti-vascular endothelial growth factor injections. Ophthalmology. 2021;S0161–6420(21):00368–7.
36.
Zurück zum Zitat Doshi RR, Leng T, Fung AE. Reducing oral flora contamination of intravitreal injections with face mask or silence. Retina Phila Pa. 2012;32(3):473–6. Doshi RR, Leng T, Fung AE. Reducing oral flora contamination of intravitreal injections with face mask or silence. Retina Phila Pa. 2012;32(3):473–6.
37.
Zurück zum Zitat Wen JC, McCannel CA, Mochon AB, Garner OB. Bacterial dispersal associated with speech in the setting of intravitreous injections. Arch Ophthalmol. 2011;129(12):1551–4. PubMedCrossRef Wen JC, McCannel CA, Mochon AB, Garner OB. Bacterial dispersal associated with speech in the setting of intravitreous injections. Arch Ophthalmol. 2011;129(12):1551–4. PubMedCrossRef
38.
Zurück zum Zitat Lau PET, Jenkins KS, Layton CJ. Current evidence for the prevention of endophthalmitis in anti-VEGF intravitreal injections. J Ophthalmol. 2018;24(2018):8567912. Lau PET, Jenkins KS, Layton CJ. Current evidence for the prevention of endophthalmitis in anti-VEGF intravitreal injections. J Ophthalmol. 2018;24(2018):8567912.
39.
Zurück zum Zitat Bhavsar AR, Glassman AR, Stockdale CR, Jampol LM. Diabetic retinopathy clinical research network. elimination of topical antibiotics for intravitreous injections and the importance of using povidone-iodine: update from the diabetic retinopathy clinical research network. JAMA Ophthalmol. 2016;134(10):1181–3. PubMedCrossRef Bhavsar AR, Glassman AR, Stockdale CR, Jampol LM. Diabetic retinopathy clinical research network. elimination of topical antibiotics for intravitreous injections and the importance of using povidone-iodine: update from the diabetic retinopathy clinical research network. JAMA Ophthalmol. 2016;134(10):1181–3. PubMedCrossRef
40.
Zurück zum Zitat Cheung CSY, Wong AWT, Lui A, Kertes PJ, Devenyi RG, Lam W-C. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology. 2012;119(8):1609–14. PubMedCrossRef Cheung CSY, Wong AWT, Lui A, Kertes PJ, Devenyi RG, Lam W-C. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology. 2012;119(8):1609–14. PubMedCrossRef
41.
Zurück zum Zitat Lyall DAM, Tey A, Foot B, Roxburgh STD, Virdi M, Robertson C, et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye. 2012;26(12):1517–26. PubMedPubMedCentralCrossRef Lyall DAM, Tey A, Foot B, Roxburgh STD, Virdi M, Robertson C, et al. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes. Eye. 2012;26(12):1517–26. PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Grzybowski A, Told R, Sacu S, Bandello F, Moisseiev E, Loewenstein A, et al. 2018 Update on intravitreal injections: euretina expert consensus recommendations. Ophthalmologica. 2018;239(4):181–93. PubMedCrossRef Grzybowski A, Told R, Sacu S, Bandello F, Moisseiev E, Loewenstein A, et al. 2018 Update on intravitreal injections: euretina expert consensus recommendations. Ophthalmologica. 2018;239(4):181–93. PubMedCrossRef
43.
Zurück zum Zitat Jiang J, Wu M, Shen T. The toxic effect of different concentrations of povidone iodine on the rabbit’s cornea. Cutan Ocul Toxicol. 2009;28(3):119–24. PubMedCrossRef Jiang J, Wu M, Shen T. The toxic effect of different concentrations of povidone iodine on the rabbit’s cornea. Cutan Ocul Toxicol. 2009;28(3):119–24. PubMedCrossRef
44.
Zurück zum Zitat Ridder WH, Oquindo C, Dhamdhere K, Burke J. Effect of povidone iodine 5% on the cornea, vision, and subjective comfort. Optom Vis Sci. 2017;94(7):732–41. PubMedCrossRef Ridder WH, Oquindo C, Dhamdhere K, Burke J. Effect of povidone iodine 5% on the cornea, vision, and subjective comfort. Optom Vis Sci. 2017;94(7):732–41. PubMedCrossRef
45.
Zurück zum Zitat Dohlman TH, Lertsuwanroj B, D’Amico DJ, Ciralsky JB, Kiss S. Evaluation of signs and symptoms of ocular surface disease after intravitreal injection. Acta Ophthalmol 1755375X. 2019;97(8):e1154-6. Dohlman TH, Lertsuwanroj B, D’Amico DJ, Ciralsky JB, Kiss S. Evaluation of signs and symptoms of ocular surface disease after intravitreal injection. Acta Ophthalmol 1755375X. 2019;97(8):e1154-6.
46.
Zurück zum Zitat Saedon H, Nosek J, Phillips J, Narendran N, Yang YC. Ocular surface effects of repeated application of povidone iodine in patients receiving frequent intravitreal injections. Cutan Ocul Toxicol. 2017;36(4):343–6. PubMedCrossRef Saedon H, Nosek J, Phillips J, Narendran N, Yang YC. Ocular surface effects of repeated application of povidone iodine in patients receiving frequent intravitreal injections. Cutan Ocul Toxicol. 2017;36(4):343–6. PubMedCrossRef
47.
Zurück zum Zitat Srinagesh V, Ellenberg D, Scharper PH, Etter J. Intravitreal dry eye study. Invest Ophthalmol Vis Sci. 2014;55(13):3696. Srinagesh V, Ellenberg D, Scharper PH, Etter J. Intravitreal dry eye study. Invest Ophthalmol Vis Sci. 2014;55(13):3696.
48.
Zurück zum Zitat Polat OA, Şener H, Erkiliç K. Corneal nerve fiber and sensitivity loss after repeated intravitreal Anti-VEGF Injections: an in vivo confocal microscopy study. Cornea. 2022;41(3):317–21. PubMedCrossRef Polat OA, Şener H, Erkiliç K. Corneal nerve fiber and sensitivity loss after repeated intravitreal Anti-VEGF Injections: an in vivo confocal microscopy study. Cornea. 2022;41(3):317–21. PubMedCrossRef
50.
Zurück zum Zitat Jandorf S, Krogh Nielsen M, Sørensen TL. Irrigating the eye after intravitreal injection reduces epithelial damage but not patient discomfort. Acta Ophthalmol 1755375X. 2019;97(4):e670-1. CrossRef Jandorf S, Krogh Nielsen M, Sørensen TL. Irrigating the eye after intravitreal injection reduces epithelial damage but not patient discomfort. Acta Ophthalmol 1755375X. 2019;97(4):e670-1. CrossRef
51.
Zurück zum Zitat Chong DY, Anand R, Williams PD, Qureshi JA, Callanan DG. Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection. Retina. 2010;30(9):1432–40. PubMedCrossRef Chong DY, Anand R, Williams PD, Qureshi JA, Callanan DG. Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection. Retina. 2010;30(9):1432–40. PubMedCrossRef
52.
Zurück zum Zitat Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–31. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–31.
53.
Zurück zum Zitat Khanani AM, Cohen GL, Zawadzki R. A prospective masked clinical assessment of inflammation after intravitreal injection of ranibizumab or aflibercept. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2016;32(4):216–8. CrossRef Khanani AM, Cohen GL, Zawadzki R. A prospective masked clinical assessment of inflammation after intravitreal injection of ranibizumab or aflibercept. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2016;32(4):216–8. CrossRef
54.
Zurück zum Zitat Souied EH, Dugel PU, Ferreira A, Hashmonay R, Lu J, Kelly SP. Severe ocular inflammation following ranibizumab or aflibercept injections for age-related macular degeneration: a retrospective claims database analysis. Ophthalmic Epidemiol. 2016;23(2):71–9. PubMedPubMedCentralCrossRef Souied EH, Dugel PU, Ferreira A, Hashmonay R, Lu J, Kelly SP. Severe ocular inflammation following ranibizumab or aflibercept injections for age-related macular degeneration: a retrospective claims database analysis. Ophthalmic Epidemiol. 2016;23(2):71–9. PubMedPubMedCentralCrossRef
55.
Zurück zum Zitat Baumal CR, Spaide RF, Vajzovic L, Freund KB, Walter SD, John V, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020;127(10):1345–59. PubMedCrossRef Baumal CR, Spaide RF, Vajzovic L, Freund KB, Walter SD, John V, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020;127(10):1345–59. PubMedCrossRef
56.
Zurück zum Zitat Agrawal S, Joshi M, Christoforidis JB. Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy. Mediators Inflamm. 2013;2013:943409. PubMedPubMedCentralCrossRef Agrawal S, Joshi M, Christoforidis JB. Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy. Mediators Inflamm. 2013;2013:943409. PubMedPubMedCentralCrossRef
57.
Zurück zum Zitat Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye. 2009;23(1):181–5. PubMedCrossRef Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye. 2009;23(1):181–5. PubMedCrossRef
58.
Zurück zum Zitat Swaminathan SS, Kunkler AL, Quan AV, Medert CM, Vanner EA, Feuer W, et al. Rates of RNFL thinning in patients with suspected or confirmed glaucoma receiving unilateral intravitreal injections for exudative AMD. Am J Ophthalmol. 2021;1(226):206–16. CrossRef Swaminathan SS, Kunkler AL, Quan AV, Medert CM, Vanner EA, Feuer W, et al. Rates of RNFL thinning in patients with suspected or confirmed glaucoma receiving unilateral intravitreal injections for exudative AMD. Am J Ophthalmol. 2021;1(226):206–16. CrossRef
59.
Zurück zum Zitat Du J, Patrie JT, Prum BE, Netland PA, Shildkrot Y (Eugene). Effects of intravitreal anti-VEGF therapy on glaucoma-like progression in susceptible eyes. J Glaucoma. 2019;28(12):1035–40. Du J, Patrie JT, Prum BE, Netland PA, Shildkrot Y (Eugene). Effects of intravitreal anti-VEGF therapy on glaucoma-like progression in susceptible eyes. J Glaucoma. 2019;28(12):1035–40.
60.
Zurück zum Zitat Mammo DA, Ringeisen AL, Parke DW. Frequency of rhegmatogenous retinal detachment after intravitreal therapy in neovascular age-related macular degeneration. Ophthalmol Retina. 2020;4(10):973–8. PubMedCrossRef Mammo DA, Ringeisen AL, Parke DW. Frequency of rhegmatogenous retinal detachment after intravitreal therapy in neovascular age-related macular degeneration. Ophthalmol Retina. 2020;4(10):973–8. PubMedCrossRef
61.
Zurück zum Zitat Storey PP, Pancholy M, Wibbelsman TD, Obeid A, Su D, Borkar D, et al. Rhegmatogenous retinal detachment after intravitreal injection of anti–vascular endothelial growth factor. Ophthalmology. 2019;126(10):1424–31. PubMedCrossRef Storey PP, Pancholy M, Wibbelsman TD, Obeid A, Su D, Borkar D, et al. Rhegmatogenous retinal detachment after intravitreal injection of anti–vascular endothelial growth factor. Ophthalmology. 2019;126(10):1424–31. PubMedCrossRef
62.
Zurück zum Zitat Arevalo JF, Maia M, Flynn HW, Saravia M, Avery RL, Wu L, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92(2):213–6. PubMedCrossRef Arevalo JF, Maia M, Flynn HW, Saravia M, Avery RL, Wu L, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92(2):213–6. PubMedCrossRef
63.
Zurück zum Zitat Antoszyk AN, Glassman AR, Beaulieu WT, Jampol LM, Jhaveri CD, Punjabi OS, et al. Effect of intravitreous aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic retinopathy. JAMA. 2020;324(23):2383–95. PubMedPubMedCentralCrossRef Antoszyk AN, Glassman AR, Beaulieu WT, Jampol LM, Jhaveri CD, Punjabi OS, et al. Effect of intravitreous aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic retinopathy. JAMA. 2020;324(23):2383–95. PubMedPubMedCentralCrossRef
64.
Zurück zum Zitat Scappaticci FA, Skillings JR, Holden SN, Gerber H-P, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. JNCI J Natl Cancer Inst. 2007;99(16):1232–9. PubMedCrossRef Scappaticci FA, Skillings JR, Holden SN, Gerber H-P, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. JNCI J Natl Cancer Inst. 2007;99(16):1232–9. PubMedCrossRef
65.
Zurück zum Zitat •• Avery RL, Gordon GM. Systemic safety of prolonged monthly anti–vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. JAMA Ophthalmol. 2016;134(1):21–9. ( This meta-analysis found an increased risk of death in patients that received monthly anti-VEGF injections over 2 years.) PubMedCrossRef •• Avery RL, Gordon GM. Systemic safety of prolonged monthly anti–vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. JAMA Ophthalmol. 2016;134(1):21–9. ( This meta-analysis found an increased risk of death in patients that received monthly anti-VEGF injections over 2 years.) PubMedCrossRef
66.
Zurück zum Zitat Maloney MH, Schilz SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. Risk of systemic adverse events associated with intravitreal anti–VEGF therapy for diabetic macular edema in routine clinical practice. Ophthalmology. 2019;126(7):1007–15. PubMedCrossRef Maloney MH, Schilz SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. Risk of systemic adverse events associated with intravitreal anti–VEGF therapy for diabetic macular edema in routine clinical practice. Ophthalmology. 2019;126(7):1007–15. PubMedCrossRef
67.
Zurück zum Zitat Starr MR, Dalvin LA, AbouChehade JE, Damento GM, Garcia MD, Shah SM, et al. Classification of strokes in patients receiving intravitreal anti-vascular endothelial growth factor. Ophthalmic Surg Lasers Imaging Retina. 2019;50(5):e140–57. PubMedCrossRef Starr MR, Dalvin LA, AbouChehade JE, Damento GM, Garcia MD, Shah SM, et al. Classification of strokes in patients receiving intravitreal anti-vascular endothelial growth factor. Ophthalmic Surg Lasers Imaging Retina. 2019;50(5):e140–57. PubMedCrossRef
68.
Zurück zum Zitat Maloney MH, Payne SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. Risk of systemic adverse events after intravitreal bevacizumab, ranibizumab, and aflibercept in routine clinical practice. Ophthalmology. 2021;128(3):417–24. PubMedCrossRef Maloney MH, Payne SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. Risk of systemic adverse events after intravitreal bevacizumab, ranibizumab, and aflibercept in routine clinical practice. Ophthalmology. 2021;128(3):417–24. PubMedCrossRef
69.
Zurück zum Zitat Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol. 2010;128(10):1273–9. PubMedCrossRef Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol. 2010;128(10):1273–9. PubMedCrossRef
71.
Zurück zum Zitat Hanna RM, Lopez EA, Hasnain H, Selamet U, Wilson J, Youssef PN, et al. Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. Clin Kidney J. 2018;12(1):92–100. PubMedPubMedCentralCrossRef Hanna RM, Lopez EA, Hasnain H, Selamet U, Wilson J, Youssef PN, et al. Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. Clin Kidney J. 2018;12(1):92–100. PubMedPubMedCentralCrossRef
72.
Zurück zum Zitat Touzani F, Geers C, Pozdzik A. Intravitreal injection of anti-VEGF antibody induces glomerular endothelial cells injury. Case Rep Nephrol. 2019;22(2019):e2919080. Touzani F, Geers C, Pozdzik A. Intravitreal injection of anti-VEGF antibody induces glomerular endothelial cells injury. Case Rep Nephrol. 2019;22(2019):e2919080.
73.
Zurück zum Zitat Hanna RM, Barsoum M, Arman F, Selamet U, Hasnain H, Kurtz I. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. Kidney Int. 2019;96(3):572–80. PubMedCrossRef Hanna RM, Barsoum M, Arman F, Selamet U, Hasnain H, Kurtz I. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. Kidney Int. 2019;96(3):572–80. PubMedCrossRef
74.
Zurück zum Zitat Meredith GGB, Schkade PA, Joondeph BCM. Allergic reaction upon intravitreal administration of anti-vascular endothelial growth factor agents. Retin Cases Brief Rep Summer 2019. 2019;13(3):287–9. Meredith GGB, Schkade PA, Joondeph BCM. Allergic reaction upon intravitreal administration of anti-vascular endothelial growth factor agents. Retin Cases Brief Rep Summer 2019. 2019;13(3):287–9.
75.
Zurück zum Zitat Nagai N, Ibuki M, Shinoda H, Kameyama K, Tsubota K, Ozawa Y. Maculopapular rash after intravitreal injection of an antivascular endothelial growth factor, aflibercept, for treating age-related macular degeneration: a case report. Medicine (Baltimore). 2017;96(21):e6965. CrossRef Nagai N, Ibuki M, Shinoda H, Kameyama K, Tsubota K, Ozawa Y. Maculopapular rash after intravitreal injection of an antivascular endothelial growth factor, aflibercept, for treating age-related macular degeneration: a case report. Medicine (Baltimore). 2017;96(21):e6965. CrossRef
76.
Zurück zum Zitat Kleris RS, Keswani A, Lugar P. The eyes have it: eyelid swelling and rash in a 79-year-old woman with macular degeneration. Allergy Rhinol. 2018;1(9):2152656718763385. Kleris RS, Keswani A, Lugar P. The eyes have it: eyelid swelling and rash in a 79-year-old woman with macular degeneration. Allergy Rhinol. 2018;1(9):2152656718763385.
77.
Zurück zum Zitat Galazios G, Papazoglou D, Tsikouras P, Kolios G. Vascular endothelial growth factor gene polymorphisms and pregnancy. J Matern Fetal Neonatal Med. 2009;22(5):371–8. PubMedCrossRef Galazios G, Papazoglou D, Tsikouras P, Kolios G. Vascular endothelial growth factor gene polymorphisms and pregnancy. J Matern Fetal Neonatal Med. 2009;22(5):371–8. PubMedCrossRef
78.
Zurück zum Zitat Choo PP, Md Din N, Azmi N, Bastion M-LC. Review of the management of sight-threatening diabetic retinopathy during pregnancy. World J Diabetes. 2021;12(9):1386–400. PubMedPubMedCentralCrossRef Choo PP, Md Din N, Azmi N, Bastion M-LC. Review of the management of sight-threatening diabetic retinopathy during pregnancy. World J Diabetes. 2021;12(9):1386–400. PubMedPubMedCentralCrossRef
79.
Zurück zum Zitat Almawi WY, Saldanha FL, Mahmood NA, Al-Zaman I, Sater MS, Mustafa FE. Relationship between VEGFA polymorphisms and serum VEGF protein levels and recurrent spontaneous miscarriage. Hum Reprod. 2013;28(10):2628–35. PubMedCrossRef Almawi WY, Saldanha FL, Mahmood NA, Al-Zaman I, Sater MS, Mustafa FE. Relationship between VEGFA polymorphisms and serum VEGF protein levels and recurrent spontaneous miscarriage. Hum Reprod. 2013;28(10):2628–35. PubMedCrossRef
80.
Zurück zum Zitat Dalal PJ, Patel AL, Carle M, Rajanala A, Gill MK. Review of ophthalmic and breastfeeding medicine evidence: real and theoretical risks of intravitreal anti-vascular endothelial growth factor administration in lactating women. Retina. 2020;40(11):2065–9. PubMedCrossRef Dalal PJ, Patel AL, Carle M, Rajanala A, Gill MK. Review of ophthalmic and breastfeeding medicine evidence: real and theoretical risks of intravitreal anti-vascular endothelial growth factor administration in lactating women. Retina. 2020;40(11):2065–9. PubMedCrossRef
Metadaten
Titel
Systemic and Ocular Adverse Events with Intravitreal Anti-VEGF Therapy Used in the Treatment of Diabetic Retinopathy: a Review
verfasst von
Jason A. Zehden
Xavier M. Mortensen
Ashvini Reddy
Alice Yang Zhang
Publikationsdatum
02.09.2022
Verlag
Springer US
Erschienen in
Current Diabetes Reports / Ausgabe 10/2022
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-022-01491-y

Weitere Artikel der Ausgabe 10/2022

Current Diabetes Reports 10/2022 Zur Ausgabe

Hospital Management of Diabetes (A Wallia and JJ Seley, Section Editors)

Potential Clinical Applications for Continuous Ketone Monitoring in the Hospitalized Patient with Diabetes

Pathogenesis of Type 2 Diabetes and Insulin Resistance (M-E Patti, Section Editor)

Growth Hormone and Counterregulation in the Pathogenesis of Diabetes

Psychosocial Aspects (J Pierce, Section Editor)

Social Care Recommendations in National Diabetes Treatment Guidelines

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.